Depomed (DEPO) Tops Q2 EPS by 3c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Depomed Announces Second-Quarter 2018 Financial Results
August 8, 2018 7:30 AM EDT-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise --
-- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --
-- Announces Agreement with PDL BioPharma to Monetize Royalty Stream; Company Received $20 Million in Cash --
-- Announces Planned Change in Company Name from Depomed to Assertio Therapeutics;Remains On-Track to Transition to New Corporate Headquarters in Lake Forest, Illinois --
LAKE FOREST, Ill., Aug. 08,... More



